No description available.

Made available in DSpace on 2017-07-21T14:13:13Z (GMT). No. of bitstreams: 1 Fabiula Franke.pdf: 1832049 bytes, checksum: 9f31a658c71b761b6dda69c029bbafb4 (MD5) Previous issue date: 2014-02-26 / The ferulic acid has antioxidant, anti-inflammatory, antithrombotic, anticancer, neuroprotective, cardioprotective and photoprotective activity. However, despite these biological activities, its therapeutic usefulness is limited due to certain unfavorable physicochemical properties, especially the low aqueous solubility. It is classified as a Class II drug by the Biopharmaceutical Classification System and therefore its dissolution is a limiting step of absorption, may present bioavailability problems. Thus, considering the large number of pharmacological properties attributed to ferulic acid, the aim of this study was to develop and characterize solid dispersions containing ferulic acid, hydrophobic, a non-ionic surfactant (Poloxamer 407) and compare them in terms of improving the dissolution of ferulic acid. Solid dispersions were obtained by methods of crushing, kneading, co-evaporation, fusion, spray drying and freeze drying at concentrations of 10 and 20%. The formulations showed a yield between 38.6 and 80.2%. All formulations showed adequate amounts of efficiency of incorporation, greater than 80%. The solid dispersions were characterized by scanning electron microscopy, X-ray diffraction and spectroscopy in the infrared region in Fourier transform, whose results confirmed the acquisition of solid dispersions. The dissolution characteristics of the pure drug and the formulations were compared. Solid dispersions exhibited greater efficiency in improving the speed of dissolution of the ferulic acid, explainable by the effect of Poloxamer 407 surfactant. A highest increase of dissolving was obtained with the formulation obtained by the method of freeze drying at a concentration of 10%, with dissolution efficiency of 93.83%. The dissolution profiles showed the best fit to a monoexponential equation. These results suggest that the solid dispersions prepared with the use of Poloxamer 407, containing the drug, are strategies feasible in the pharmaceutical industry. / O ácido ferúlico tem atividade antioxidante, anti-inflamatória, antitrombótica, anticancerígena, neuroprotetora, cardioprotetora e fotoprotetora. No entanto, apesar dessas atividades biológicas, sua utilidade terapêutica é limitada devido a certas propriedades físico-químicas desfavoráveis, notadamente a baixa solubilidade aquosa. É qualificado como fármaco da Classe II pelo Sistema de Classificação Biofarmacêutica e, portanto, sua dissolução é etapa limitante da absorção, podendo apresentar problemas de biodisponibilidade. Assim, considerando o elevado número de propriedades farmacológicas atribuídas ao ácido ferúlico, o objetivo desse trabalho foi desenvolver e caracterizar dispersões sólidas contendo ácido ferúlico, hidrofóbico, e um surfactante não-iônico Poloxamer 407 e compará-las quanto à melhoria na dissolução do ácido ferúlico. As dispersões sólidas foram obtidas pelos métodos de trituração, malaxagem, coevaporação, fusão, liofilização e spray-drying nas concentrações de 10 e 20%. As formulações apresentaram um rendimento entre 38,6 e 80,2%. Todas as formulações mostraram valores de eficiência de incorporação adequados, superiores a 80%. As dispersões sólidas foram caracterizadas por microscopia eletrônica de varredura, por difração de raios X e por espectroscopia na região do infravermelho com transformada em Fourier, cujos resultados comprovaram a obtenção das dispersões sólidas. As características de dissolução entre o fármaco puro e as formulações foram comparadas. As dispersões sólidas apresentaram maior eficiência em melhorar a velocidade de dissolução do ácido ferúlico, explicável pelo efeito tensoativo do Poloxamer 407. Maior incremento da dissolução foi obtido com a formulação obtida pelo método de liofilização na concentração de 10%, com eficiência de dissolução de 93,83%. Os perfis de dissolução apresentaram o melhor ajuste para a equação monoexponencial. Esses resultados sugerem que as dispersões sólidas elaboradas com o uso do Poloxamer 407, contendo o fármaco, são estratégias viáveis na indústria farmacêutica.

Doctor of Philosophy(PhD) / Owing to its strategic position in the liver sinusoid, pathologic and morphologic alterations of the Liver Sinusoidal Endothelial Cell (LSEC) have far-reaching repercussions for the whole liver and systemic metabolism. LSECs are perforated with fenestrations, which are pores that facilitate the transfer of lipoproteins and macromolecules between blood and hepatocytes. Loss of LSEC porosity is termed defenestration, which can result from loss of fenestrations and/ or decreases in fenestration diameter. Gram negative bacterial endotoxin (Lipopolysaccharide, LPS) has marked effects on LSEC morphology, including induction LSEC defenestration. Sepsis is associated with hyperlipidemia, and proposed mechanisms include inhibition of tissue lipoprotein lipase and increased triglyceride production by the liver. The LSEC has an increasingly recognized role in hyperlipidemia. Conditions associated with reduced numbers of fenestrations such as ageing and bacterial infections are associated with impaired lipoprotein and chylomicron remnant uptake by the liver and consequent hyperlipidemia. Given the role of the LSEC in liver allograft rejection and hyperlipidemia, changes in the LSEC induced by LPS may have significant clinical implications. In this thesis, the following major hypotheses are explored: 1. The Pseudomonas aeruginosa toxin pyocyanin induces defenestration of the LSEC both in vitro and in vivo 2. The effects of pyocyanin on the LSEC are mediated by oxidative stress 3. Defenestration induced by old age and poloxamer 407 causes intrahepatocytic hypoxia and upregulation of hypoxia-related responses 4. Defenestration of the LSEC seen in old age can be exacerbated by diabetes mellitus and prevented or ameliorated by caloric restriction commencing early in life

Doctor of Philosophy(PhD) / Owing to its strategic position in the liver sinusoid, pathologic and morphologic alterations of the Liver Sinusoidal Endothelial Cell (LSEC) have far-reaching repercussions for the whole liver and systemic metabolism. LSECs are perforated with fenestrations, which are pores that facilitate the transfer of lipoproteins and macromolecules between blood and hepatocytes. Loss of LSEC porosity is termed defenestration, which can result from loss of fenestrations and/ or decreases in fenestration diameter. Gram negative bacterial endotoxin (Lipopolysaccharide, LPS) has marked effects on LSEC morphology, including induction LSEC defenestration. Sepsis is associated with hyperlipidemia, and proposed mechanisms include inhibition of tissue lipoprotein lipase and increased triglyceride production by the liver. The LSEC has an increasingly recognized role in hyperlipidemia. Conditions associated with reduced numbers of fenestrations such as ageing and bacterial infections are associated with impaired lipoprotein and chylomicron remnant uptake by the liver and consequent hyperlipidemia. Given the role of the LSEC in liver allograft rejection and hyperlipidemia, changes in the LSEC induced by LPS may have significant clinical implications. In this thesis, the following major hypotheses are explored: 1. The Pseudomonas aeruginosa toxin pyocyanin induces defenestration of the LSEC both in vitro and in vivo 2. The effects of pyocyanin on the LSEC are mediated by oxidative stress 3. Defenestration induced by old age and poloxamer 407 causes intrahepatocytic hypoxia and upregulation of hypoxia-related responses 4. Defenestration of the LSEC seen in old age can be exacerbated by diabetes mellitus and prevented or ameliorated by caloric restriction commencing early in life